KRAS and BRAF mutations modify adjuvant chemotherapy outcomes in early stage colorectal cancer

Abstract KRAS and BRAF V600E mutations are established biomarkers in metastatic colorectal cancer (CRC), but their predictive roles in early-stage disease remain uncertain. We aimed to determine whether KRAS and BRAF V600E mutations modify the association between adjuvant chemotherapy regimen and su...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Durgesh Wankhede, Mary Jose Urruchua Rodriguez, Dominic Edelmann, Matthias Kloor, Hendrik Bläker, Alexander Brobeil, Wilfried Roth, Hermann Brenner, Michael Hoffmeister
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Nature Portfolio 2026-05-01
Saila:	npj Precision Oncology
Sarrera elektronikoa:	https://doi.org/10.1038/s41698-026-01494-y
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!